Title: Integrin #5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis
and immunotherapy efficacy in gastric cancer
Version: 1 Date: 29 Aug 2024
Reviewer's report:
Dear Colleague,
Thank you for addressing all the questions.
While we may have differing views on some points, I appreciate your input.
However, it is important to include in the limitations section that the limited sample size
prevented you from adequately controlling for all potential confounding factors. Although Cox
regression can account for some variables, the small patient cohort made it challenging to do
so effectively was my point.
Title: Integrin #5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis
and immunotherapy efficacy in gastric cancer
Version: 1 Date: 29 Aug 2024
Reviewer's report:
Dear Colleague,
Thank you for addressing all the questions.
While we may have differing views on some points, I appreciate your input.
However, it is important to include in the limitations section that the limited sample size
prevented you from adequately controlling for all potential confounding factors. Although Cox
regression can account for some variables, the small patient cohort made it challenging to do
so effectively was my point.
Please review this paper.
user
Title: Integrin #5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis
and immunotherapy efficacy in gastric cancer
Version: 1 Date: 29 Aug 2024
Reviewer's report:
Dear Colleague,
Thank you for addressing all the questions.
While we may have differing views on some points, I appreciate your input.
However, it is important to include in the limitations section that the limited sample size
prevented you from adequately controlling for all potential confounding factors. Although Cox
regression can account for some variables, the small patient cohort made it challenging to do
so effectively was my point.
assistant